| Single-cell analysis reveals new evolutionary complexity in uveal melanoma MA Durante, DA Rodriguez, S Kurtenbach, JN Kuznetsov, MI Sanchez, ... Nature communications 11 (1), 496, 2020 | 343 | 2020 |
| PRAME as an independent biomarker for metastasis in uveal melanoma MG Field, CL Decatur, S Kurtenbach, G Gezgin, PA Van Der Velden, ... Clinical cancer research 22 (5), 1234-1242, 2016 | 287 | 2016 |
| Driver mutations in uveal melanoma: associations with gene expression profile and patient outcomes CL Decatur, E Ong, N Garg, H Anbunathan, AM Bowcock, MG Field, ... JAMA ophthalmology 134 (7), 728-733, 2016 | 265 | 2016 |
| L-DOPA Is an Endogenous Ligand for OA1 VM Lopez, CL Decatur, WD Stamer, RM Lynch, BS McKay PLoS biology 6 (9), e236, 2008 | 212 | 2008 |
| Punctuated evolution of canonical genomic aberrations in uveal melanoma MG Field, MA Durante, H Anbunathan, LZ Cai, CL Decatur, AM Bowcock, ... Nature communications 9 (1), 116, 2018 | 185 | 2018 |
| Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas MG Field, MA Durante, CL Decatur, B Tarlan, KM Oelschlager, JF Stone, ... Oncotarget 7 (37), 59209, 2016 | 136 | 2016 |
| Gene expression profiling and PRAME status versus tumor-node-metastasis staging for prognostication in uveal melanoma L Cai, M Paez-Escamilla, SD Walter, B Tarlan, CL Decatur, BM Perez, ... American journal of ophthalmology 195, 154-160, 2018 | 66 | 2018 |
| BAP1 loss is associated with DNA methylomic repatterning in highly aggressive class 2 uveal melanomas MG Field, JN Kuznetsov, PL Bussies, LZ Cai, KA Alawa, CL Decatur, ... Clinical Cancer Research 25 (18), 5663-5673, 2019 | 65 | 2019 |
| Intravitreal injection analysis at the Bascom Palmer Eye Institute: evaluation of clinical indications for the treatment and incidence rates of endophthalmitis LL Cavalcante, ML Cavalcante, TG Murray, MM Vigoda, Y Piña, ... Clinical Ophthalmology, 519-524, 2010 | 47 | 2010 |
| 2016 H Field, MA Durante, CL Decatur, B Tarlan, KM Oelschlager, JF Stone Science without Numbers, 1980 | 47 | 1980 |
| 2-deoxy-glucose downregulates endothelial AKT and ERK via interference with N-linked glycosylation, induction of endoplasmic reticulum stress, and GSK3β activation K Kovács, C Decatur, M Toro, DG Pham, H Liu, Y Jing, TG Murray, ... Molecular cancer therapeutics 15 (2), 264-275, 2016 | 37 | 2016 |
| Intravitreal bevacizumab combined with plaque brachytherapy reduces melanoma tumor volume and enhances resolution of exudative detachment SK Houston, NV Shah, C Decatur, M Lonngi, W Feuer, AM Markoe, ... Clinical Ophthalmology, 193-198, 2013 | 26 | 2013 |
| BAP1 loss promotes suppressive tumor immune microenvironment via upregulation of PROS1 in class 2 uveal melanomas CJ Kaler, JJ Dollar, AM Cruz, JN Kuznetsoff, MI Sanchez, CL Decatur, ... Cancers 14 (15), 3678, 2022 | 23 | 2022 |
| Intravitreal and subconjunctival melphalan for retinoblastoma in transgenic mice NV Shah, DG Pham, TG Murray, C Decatur, E Hernandez, NN Shah, ... Journal of Ophthalmology 2014 (1), 829879, 2014 | 22 | 2014 |
| Retinoblastoma treatment: utilization of the glycolytic inhibitor, 2-deoxy-2-fluoro-D-glucose (2-FG), to target the chemoresistant hypoxic regions in LHBETATAG retinal tumors Y Pina, C Decatur, TG Murray, SK Houston, M Lopez-Cavalcante, ... Investigative ophthalmology & visual science 53 (2), 996-1002, 2012 | 21 | 2012 |
| Advanced retinoblastoma treatment: targeting hypoxia by inhibition of the mammalian target of rapamycin (mTOR) in LHBETATAG retinal tumors Y Piña, C Decatur, TG Murray, SK Houston, D Gologorsky, M Cavalcante, ... Clinical Ophthalmology, 337-343, 2011 | 19 | 2011 |
| Retinoblastoma treatment: impact of the glycolytic inhibitor 2-deoxy-d-glucose on molecular genomics expression in LHBETATAG retinal tumors Y Piña, SK Houston, TG Murray, T Koru-Sengul, C Decatur, WK Scott, ... Clinical Ophthalmology, 817-830, 2012 | 15 | 2012 |
| Microincisional vitrectomy for retinal detachment in I-125 brachytherapy-treated patients with posterior uveal malignant melanoma M Lonngi, SK Houston, TG Murray, RA Sisk, CL Decatur, M Cavalcante, ... Clinical Ophthalmology, 427-435, 2013 | 13 | 2013 |
| Genomic evolution of uveal melanoma arising in ocular melanocytosis MA Durante, MG Field, MI Sanchez, KR Covington, CL Decatur, ... Molecular Case Studies 5 (4), a004051, 2019 | 12 | 2019 |
| PRAME induces genomic instability in uveal melanoma S Kurtenbach, MI Sanchez, J Kuznetsoff, DA Rodriguez, N Weich, ... Oncogene 43 (8), 555-565, 2024 | 10* | 2024 |
